NCT03473613 is a Phase 3 clinical trial of Oral Cabergoline in Ovarian Hyperstimulation, sponsored by Benha University.

Who is sponsoring NCT03473613?

NCT03473613 is sponsored by Benha University.

What drugs are being tested in NCT03473613?

Interventions in NCT03473613: Oral Cabergoline, Calcium Gluconate.

What condition does NCT03473613 study?

NCT03473613 studies Ovarian Hyperstimulation.

Is NCT03473613 still recruiting?

NCT03473613 is currently completed. Last updated 29 March 2018.

Last reviewed 2018-03-29 · How we verify

NCT03473613

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

Completed Phase 3 Last updated 29 March 2018

What this trial tests

Phase 3 trial testing Oral Cabergoline in Ovarian Hyperstimulation in 230 participants. Completed in 15 April 2017.

Timeline

1 October 2014

Primary endpoint
15 April 2017

15 April 2017

Quick facts

Lead sponsor	Benha University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	230
Start date	1 October 2014
Primary completion	15 April 2017
Estimated completion	15 April 2017
Sites	1 location across Egypt

Drugs / interventions tested

Oral Cabergoline — full drug profile →
Calcium Gluconate (CALCIUM GLUCONATE) — full drug profile →

Conditions studied

Ovarian Hyperstimulation — all drugs for Ovarian Hyperstimulation →

Sponsor

Benha University

Who can join

Adults 18 to 45, female only, with Ovarian Hyperstimulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Benha University trials

Trials by the same sponsor.

NCT07526675 — Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer · NA · not yet recruiting
NCT07480031 — Determination of the Optimal Inspiratory Pressure to Decrease Incidence of Gastric Insufflation With Adequate Ventilatio · NA · not yet recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07467356 — Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip · Phase 3 · recruiting
NCT07300787 — miRNA in Pediatric Gastritis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03473613 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Benha University
Last refreshed: 29 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03473613.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing